Recent Updates — KROS
On September 29, 2026, Keros Therapeutics announced it will receive a $20 million development milestone payment from partner Takeda Pharmaceuticals following the dosing of the first patient in the ELRiSE MF Phase 3 clinical trial for elritercept. The company expects to distribute 25% of the net cash proceeds from this payment to its stockholders upon receipt. This milestone is part of a global license agreement effective January 16, 2025, which included a $200 million upfront payment and offers potential additional milestones exceeding $1.1 billion plus tiered royalties. Keros Therapeutics operates as a clinical-stage biopharmaceutical company focused on developing novel therapeutics for disorders linked to dysfunctional TGF-ß signaling.
Keros Therapeutics, Inc. announced on September 28, 2026, that the first patient was dosed in its Phase 2 clinical trial of rinvatercept for Duchenne muscular dystrophy (DMD). The open-label, multi-cohort basket trial aims to assess safety, tolerability, pharmacokinetics, and functional improvements in late-ambulatory and early non-ambulatory patients. Initial data from this study is expected in the first half of 2027. Keros Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company focused on developing novel therapeutics for disorders linked to dysfunctional TGF-ß signaling.
Keros Therapeutics announced a new $5 million stock repurchase program approved by its Board of Directors on September 8, 2026. This authorization follows the receipt of a $20 million development milestone payment from Takeda Pharmaceuticals U.S.A., Inc. under their license agreement for elritercept, triggered by the dosing of the first patient in the ELRiSE MDS clinical trial. The company reported cash and cash equivalents of $257.6 million as of June 30, 2026, and anticipates sufficient liquidity to fund operations through the second half of 2028 after accounting for the milestone and repurchase program. Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for disorders linked to dysfunctional signaling of the TGF-ß family of proteins.
Keros Therapeutics, Inc. filed a Form 8-K to furnish its August 2026 corporate presentation under Regulation FD. The filing updates investor materials regarding the company's pipeline of TGF-β superfamily modulators, specifically rinvatercept (KER-065) and elritercept (KER-050). Rinvatercept is in Phase 2 trials for Duchenne muscular dystrophy with initial data expected in early 2027, while elritercept is under a global license agreement with Takeda Pharmaceuticals following a $200 million upfront payment. Keros Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company developing therapies for neuromuscular and hematologic disorders.
Keros Therapeutics reported a net loss of $28.7 million for the quarter ended June 30, 2026, compared to a $30.7 million loss in the prior year period. The reduction was driven by decreased research and development expenses of $21.2 million due to the transition of elritercept-related costs to Takeda and corporate restructuring, as well as lower general and administrative expenses. Cash and cash equivalents stood at $257.6 million as of June 30, 2026, with management expecting this balance to fund operations into the first half of 2028. The company also announced it has initiated a Phase 2 clinical trial for rinvatercept in patients with Duchenne muscular dystrophy (DMD). Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for disorders linked to dysfunctional TGF-ß signaling.
On July 30, 2026, Keros Therapeutics announced it will receive a $20 million development milestone payment from partner Takeda Pharmaceuticals. This payment is triggered by the dosing of the first patient in the ELRiSE MDS clinical trial, a Phase 3 study evaluating elritercept for anemia associated with myelodysplastic syndromes. Under the global license agreement effective January 16, 2025, Keros previously received a $200 million upfront payment and retains eligibility for up to $1.1 billion in additional milestones plus tiered royalties. The company intends to distribute 25% of the net cash proceeds from this milestone to stockholders following receipt. Keros Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for disorders linked to dysfunctional TGF-ß signaling.